Annual Meeting Program Committee Chair Marcia R. Cruz-Correa, MD, PhD, shares a few highlights from Saturday’s schedule to help plan your day.

Julie R. Brahmer, MD, MSc, and Timothy A. Yap, MD, PhD, preview the Annual Meeting’s four Clinical Trials Plenary Sessions, which will include important studies looking at cellular therapies, novel immunotherapeutics, and molecularly targeted therapeutics.

Steven A. Rosenberg, MD, PhD, FAACR, is being recognized for pioneering the development of effective immunotherapies and gene therapies for patients with advanced cancers, among other significant research contributions.

This year’s multidisciplinary program reflects the AACR’s focus on the various facets of cancer etiology, progression, and treatment and the factors that influence each individual patient’s experience, including genetics, environment, and lifestyle factors.

This year’s class of 33 new Fellows joins the 256 distinguished scientists, clinicians, and physician-scientists previously honored with the AACR’s highest level of recognition.

Hunter is being honored for the discovery of protein tyrosine phosphorylation as a common cellular mechanism capable of contributing to cellular growth and proliferation and, in some cases, the development of cancer.

DuBois is being honored for elucidating the role of cyclooxygenase 2 in colon cancer and the contributions of the lipid metabolite prostaglandin E2 to tissue inflammation in the etiology of colon cancer.